<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Virol J</journal-id><journal-id journal-id-type="iso-abbrev">Virol. J</journal-id><journal-title-group><journal-title>Virology Journal</journal-title></journal-title-group><issn pub-type="epub">1743-422X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5833045</article-id><article-id pub-id-type="publisher-id">946</article-id><article-id pub-id-type="doi">10.1186/s12985-018-0946-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Echeverr&#x000ed;a</surname><given-names>Natalia</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chiodi</surname><given-names>Daniela</given-names></name><address><email>chiodi.pd@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez</surname><given-names>Pablo</given-names></name><address><email>pablolopezpedrozo@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Sanchez Ciceron</surname><given-names>Adriana</given-names></name><address><email>adriana@sanchez.com.uy</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Angulo</surname><given-names>Jenniffer</given-names></name><address><email>jenniffer.at@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>L&#x000f3;pez-Lastra</surname><given-names>Marcelo</given-names></name><address><email>lopezlastra@gmail.com</email></address><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Silvera</surname><given-names>Paola</given-names></name><address><email>paolasilvera75@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Canavesi</surname><given-names>Adrian</given-names></name><address><email>adrian1899@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bianchi</surname><given-names>Carla</given-names></name><address><email>carlabianchinaddeo@gmail.com</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Colistro</surname><given-names>Valentina</given-names></name><address><email>valentinacolistro@gmail.com</email></address><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Cristina</surname><given-names>Juan</given-names></name><address><email>juan.cristinag@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hernandez</surname><given-names>Nelia</given-names></name><address><email>hernandez.nelia@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-6155-7206</contrib-id><name><surname>Moreno</surname><given-names>Pilar</given-names></name><address><phone>(+598) 25250800</phone><email>pmoreno@cin.edu.uy</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121657640</institution-id><institution-id institution-id-type="GRID">grid.11630.35</institution-id><institution>Laboratorio de Virolog&#x000ed;a Molecular, Centro de Investigaciones Nucleares, </institution><institution>Facultad de Ciencias, Universidad de la Rep&#x000fa;blica, </institution></institution-wrap>2055 Montevideo, Mataojo Uruguay </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121657640</institution-id><institution-id institution-id-type="GRID">grid.11630.35</institution-id><institution>Cl&#x000ed;nica de Gastroenterolog&#x000ed;a, Hospital de Cl&#x000ed;nicas, Facultad de Medicina, Universidad de la Rep&#x000fa;blica, </institution></institution-wrap>11600 Montevideo, Uruguay </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121657640</institution-id><institution-id institution-id-type="GRID">grid.11630.35</institution-id><institution>Departamento de Laboratorio Cl&#x000ed;nico, Hospital de Cl&#x000ed;nicas, </institution><institution>Facultad de Medicina, Universidad de la Rep&#x000fa;blica, </institution></institution-wrap>Montevideo, Uruguay </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2157 0406</institution-id><institution-id institution-id-type="GRID">grid.7870.8</institution-id><institution>Laboratorio de Virolog&#x000ed;a Molecular, Instituto Milenio de Inmunolog&#x000ed;a e Inmunoterapia, Centro de Investigaciones M&#x000e9;dicas, Pontificia Universidad Cat&#x000f3;lica de Chile, </institution></institution-wrap>Santiago, Chile </aff><aff id="Aff5"><label>5</label>Sanatorio SEMM-Mautone, Maldonado, Uruguay </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121657640</institution-id><institution-id institution-id-type="GRID">grid.11630.35</institution-id><institution>Departamento de Gen&#x000e9;tica, </institution><institution>Facultad de Medicina, Universidad de la Rep&#x000fa;blica, </institution></institution-wrap>Montevideo, Uruguay </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>2</day><month>3</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>15</volume><elocation-id>40</elocation-id><history><date date-type="received"><day>12</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>5</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2018</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Host single-nucleotide polymorphisms (SNPs) near the interleukin 28B (<italic>IL28B</italic>) locus are associated with sustained virological response to antiviral therapy and with spontaneous Hepatitis C Virus (HCV) clearance. Prevalence of these SNPs varies depending on ethnicity. The impact of IL28B SNPs in HCV-infected patients is currently unknown in Uruguay. Therefore, the aim of this study was to evaluate and compare the distribution of polymorphisms in the IL28B gene (rs12979860 and rs8099917) among HCV-infected patients and healthy individuals in Uruguay and thus assess their possible association with the establishment of HCV infection.</p></sec><sec><title>Methods</title><p id="Par2">DNA was recovered from 92 non-infected individuals and 78 HCV-infected patients and SNPs were determined by RFLP and allelic discrimination by real-time PCR.</p></sec><sec><title>Results</title><p id="Par3">The distribution of rs12979860 genotypes for the infected population was 29.5%-CC, 47.4%-CT and 23.1%-TT and for the control group 45.7%, 42.4% and 11.9%, respectively. Prevalence in both infected and uninfected individuals is similar to that reported in other countries with admixed populations. The distribution of rs8099917 genotypes for the infected population was 57.7%-TT, 27.2%-TG and 14.1%-GG and for the control group 60.9%, 33.7% and 5.4%, respectively. The comparison of rs12979860 genotype distribution between the two populations evidenced a higher prevalence of the favourable genotype (CC) in the uninfected control group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Additionally, results generated using logistic regression analysis show that individuals carrying rs12979860-TT or CT genotypes have a higher likelihood of developing chronic hepatitis upon infection with HCV, when compared to CC carriers, considering rs8099917 genotype as constant.</p></sec><sec><title>Conclusion</title><p id="Par4">Patients with HCV infection have a statistically significant lower prevalence of the favourable rs12979860 genotype when compared to uninfected individuals; therefore we can establish that only IL28B rs12979860-CT and TT genotypes seem to contribute to the occurrence of chronic HCV infection in the cohort of Uruguayan population studied. Considering that a trend towards a higher frequency of &#x0201c;good&#x0201d; response genotypes was observed in responder patients, we believe that IL28B rs12979860 genotyping could be a useful tool for predicting different therapies outcome, including in the DAA era.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1186/s12985-018-0946-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>rs12979860</kwd><kwd>rs8099917</kwd><kwd>Hepatitis C</kwd><kwd>Genotypic distribution</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par12">With an estimate of 71 million infected individuals worldwide, Hepatitis C virus (HCV) represents a major health problem and is currently the leading cause of cirrhosis, hepatocellular carcinoma and an indication for liver transplantation worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. Despite the recent development of highly effective compounds, direct-acting agents (DAAs), designed to specifically block HCV replication, the combination of pegylated interferon alpha (peg-IFN-&#x003b1;) plus ribavirin (RBV) is still the main option for HCV treatment in several countries, including Uruguay. This therapy, however, only yields a sustained virological response (SVR) in about half of the treated patients when infected with HCV genotype 1; the most prevalent genotype in Uruguay [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>]. The poor response to treatment, its high cost, as well as the frequent occurrence of severe side effects associated to the use of peg-IFN-&#x003b1;/RBV [<xref ref-type="bibr" rid="CR5">5</xref>], highlight the relevance of enabling the means for predicting the patient&#x02019;s response to antiviral therapy. This would allow an early selection of the most adequate cost-effective HCV treatment for each particular patient. Different predictors of SVR are known, some of which are linked to the virus (genotype, viral load) whereas others are linked to the host (age, sex, race, liver fibrosis, genetic factors) [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par13">Among the host factors known to be associated with the outcome of HCV-treatment, specific single-nucleotide polymorphisms (SNPs) located near the interleukin 28B (IL28B) gene (which codes for IFN-&#x003bb;-3) have shown a significant relationship with both spontaneous virus clearance and response to peg-IFN-&#x003b1;/RBV treatment [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Patients carrying the &#x0201c;good&#x0201d; response genotypes (major allele in homozygosity) are more likely to resolve the infection than those carrying the &#x0201c;poor&#x0201d; response genotypes (risk allele in homozygosity or heterozygosity) [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR9">9</xref>]. Since its characterization, IL28B genotyping has proven useful in guiding clinicians towards the selection of the most adequate patient-personalized therapy [<xref ref-type="bibr" rid="CR11">11</xref>]. Nevertheless the strong predictive value of these SNPs is only applicable for patients infected with HCV genotypes 1 and 4 [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. In cases of infection with genotypes 2 or 3 IL28B SNP information is valuable only for patients with detectable levels of HCV RNA at week 4 (absence of rapid virological response) [<xref ref-type="bibr" rid="CR14">14</xref>]. Interestingly, IL28B genotyping has also proven relevant to anticipate HCV SVR in regimens using DAAs either in combination with IFN [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>] or in its absence [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p id="Par14">Ethnicity is also a host factor that correlates with the patient&#x02019;s ability to respond to antiviral treatment [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. This phenomenon has been partly explained by the prevalence of IL28B polymorphisms within different ethnic groups [<xref ref-type="bibr" rid="CR23">23</xref>]. For example, the major C allele (&#x0201c;good&#x0201d; response allele) of rs12979860 SNP in the general population has a frequency of 0.23&#x02013;0.55 among Africans, 0.53&#x02013;0.80 among Europeans and 0.66&#x02013;1.00 among Asians [<xref ref-type="bibr" rid="CR24">24</xref>]. In this context, Asians and Europeans are better responders to peg-IFN-&#x003b1;/RBV treatment than African-descendants [<xref ref-type="bibr" rid="CR22">22</xref>]. The case for Latin America is less clear as the prevalence of these IL28B SNPs is known only in a few countries [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>]. Furthermore, given the admixed genetic background of the Latin American populations, it is unreasonable to assume an equivalent distribution of IL28B SNPs in all South America. In fact, when comparing different populations from Latin America a sharp difference in allele frequencies for IL28B is observed [<xref ref-type="bibr" rid="CR24">24</xref>]. For example, the C allele is less prevalent in Mexico (0.38&#x02013;0.56) than in Brazil (0.64&#x02013;0.824) [<xref ref-type="bibr" rid="CR24">24</xref>]. To date no genetic information regarding IL28B SNP prevalence is available for the Uruguayan population. Noteworthy, the Uruguayan population exhibits a European, Amerindian, and African contribution to ancestry, being the Europeans the main contributors [<xref ref-type="bibr" rid="CR32">32</xref>]. The contribution of Amerindians and Africans to the Uruguayan ancestry largely varies throughout the country stressing the heterogeneity of this South American population [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par15">Hence, the aim of this study was to determine the prevalence of IL28B polymorphisms (rs12979860 C&#x02009;&#x0003e;&#x02009;T and rs8099917 T&#x02009;&#x0003e;&#x02009;G) in treatment-na&#x000ef;ve HCV-infected patients using uninfected individuals as controls and thus assess their possible association with the establishment of HCV infection. The results suggest that in Uruguay the prevalence of the favourable rs12979860 genotype (CC) is higher in the control group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Additionally, considering rs8099917 genotype constant, individuals carrying rs12979860-TT or CT genotypes have a higher likelihood of developing chronic hepatitis upon infection with HCV, when compared to CC carriers.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study population</title><p id="Par16">A cross-sectional and observational study was conducted in Uruguayan individuals with and without HCV infection, recruited between 2014 and 2015 at the Gastroenterology Clinic from Hospital de Cl&#x000ed;nicas (Control group, <italic>n</italic>&#x02009;=&#x02009;92; HCV-infected group, <italic>n</italic>&#x02009;=&#x02009;78). Chronic HCV-infected patients were treatment na&#x000ef;ve and over 18&#x000a0;years old. All samples analysed in this study were negative for hBsAg and HIV and in the case of the control group, all individuals showed absence of reactive serology for HCV. The information obtained from the study populations included sex and age. For the HCV-infected patients virus genotype and stage of liver disease were included, if previously determined (See Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Additionally, 48 of the 78 enrolled HCV-infected patients underwent dual therapy (peg-IFN-&#x003b1; plus RBV) during the study, 42 of which had completed it by the time of writing. SVR was defined as absence HCV RNA in serum 24&#x000a0;weeks after the end of treatment. Non-response (NR) to therapy was defined as HCV viral load decline less than 2 logs at week 12 during therapy or detectable serum HCV RNA at any other time during therapy. Relapse (R) was defined as undetectable level of HCV RNA by the end of treatment which becomes detectable after discontinuation of therapy. For analyses, we divided patients into two groups: patients who achieved SVR and those who did not (NR and R).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic characteristics of both populations studied</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Total population (<italic>n</italic>&#x02009;=&#x02009;170)</th><th>HCV-infected population (<italic>n</italic>&#x02009;=&#x02009;78)</th><th>Uninfected population (<italic>n</italic>&#x02009;=&#x02009;92)</th><th>Statistical test and value</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="6">
<italic>Gender</italic>
</td></tr><tr><td>&#x02003;Male (%)</td><td>115 (67.6)</td><td>48 (61.5)</td><td>67 (72.8)</td><td>&#x003c7;<sup>2</sup> 2.457</td><td char="." align="char">0.117</td></tr><tr><td>&#x02003;Female (%)</td><td>55 (32.4)</td><td>30 (38.5)</td><td>25 (27.2)</td><td/><td/></tr><tr><td>
<italic>Age (years), (mean&#x02009;&#x000b1;&#x02009;SD)</italic>
</td><td>42.7&#x02009;&#x000b1;&#x02009;12.6</td><td>46.3&#x02009;&#x000b1;&#x02009;13.1</td><td>40&#x02009;&#x000b1;&#x02009;11.4</td><td>t&#x02009;=&#x02009;3.230</td><td char="." align="char">0.002*</td></tr><tr><td colspan="6">
<italic>Genotype (n&#x02009;=&#x02009;78), n (%)</italic>
</td></tr><tr><td>&#x02003;G1</td><td>45 (57.7)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;G2</td><td>3 (3.8)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;G3</td><td>12 (15.4)</td><td/><td/><td/><td/></tr><tr><td>Not determined</td><td>18 (23.1)</td><td/><td/><td/><td/></tr><tr><td colspan="6">
<italic>Liver Stage (n&#x02009;=&#x02009;49), n (%)</italic>
</td></tr><tr><td>&#x02003;1</td><td>10 (20.4)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;2</td><td>10 (20.4)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;3</td><td>5 (10.2)</td><td/><td/><td/><td/></tr><tr><td>&#x02003;4</td><td>24 (49.0)</td><td/><td/><td/><td/></tr></tbody></table><table-wrap-foot><p>&#x003c7;<sup>2</sup> Chi-square test; t: Student&#x02019;s t-test; *<italic>p</italic> &#x0003c; 0.05</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Ethical and regulatory considerations</title><p id="Par17">The study was conducted according to national and international ethical guidelines (good clinical practice, Nuremberg statements, Declaration of Helsinki) and local regulatory rules (Mercosur Standards/GMC/RES No. 129/96). The protocol was approved by the Ethics Committee of the Hospital de Cl&#x000ed;nicas on October 24th, 2014 and all patients gave written informed consent. Access to personal information was restricted to the medical doctors. The genetic information extracted from the samples was used exclusively for the purposes of this study.</p></sec><sec id="Sec5"><title>Genotyping of SNPs rs12979860 and rs8099917</title><p id="Par18">Genomic DNA was extracted from peripheral white blood cells by QIAamp DNA Kit (QIAGEN). All samples from HCV-infected individuals were SNP genotyped by end-point PCR amplification following restriction fragment length polymorphism analysis as previously described [<xref ref-type="bibr" rid="CR33">33</xref>]. For rs12979860 primers used were: rs12-F 5&#x02019;-GCGGAAGGAGCAGTTGCGCT-3&#x02032; (sense) and bst-R 5&#x02019;-GGGGCTTTGCTGGGGGAGTG-3&#x02032; (antisense). For rs8099917 primers used were: rs80-F 5&#x02019;-CCCACTTCTGGAACAAATCGTCCC-3&#x02032; (sense) and rs80-R 5&#x02019;-TCTCCTCCCCAAGTCAGGCAACC-3&#x02032; (antisense) [<xref ref-type="bibr" rid="CR33">33</xref>]. All samples from the control group were genotyped by real-time PCR using TaqMan SNP allelic discrimination assays carried out using StepOne Real-Time PCR System (Applied Biosystems). The primers, MGB probes and conditions used to amplify rs12979860 have been previously described [<xref ref-type="bibr" rid="CR27">27</xref>]. The rs8099917 SNP genotyping was determined by a TaqMan&#x000ae; Pre-designed SNP Assay (Applied Biosystems) (AB) reference: C_11710096_10. Genotyping of each sample was attributed automatically by the StepOne Software v2.2.2. Positive and negative controls (previously verified by direct Sanger sequencing) were used in each genotyping assay.</p></sec><sec id="Sec6"><title>Statistical analyses</title><p id="Par19">Data are presented as percentages (categorical variables), means and standard deviations (continuous variables). Comparisons between the two groups were made using the chi-square (<italic>&#x003c7;</italic><sup>2</sup>) test or Fisher&#x02019;s exact test (when cell sample sizes were less than five) for categorical variables and Student&#x02019;s t-test for continuous variables. The existence of differences in genotypic frequencies between groups was assessed by Chi-square test under the three main inheritance models: codominant, dominant and recessive. A Monte Carlo permutation method was used for multiple test correction. A <italic>p</italic> value less than 0.05 was considered statistically significant. Raw <italic>p</italic> values are shown in the tables. Possible deviations from Hardy-Weinberg equilibrium were studied in the control population (both exact and Chi-squared tests were performed) using PLINK Package version 1.9 (<ext-link ext-link-type="uri" xlink:href="http://zzz.bwh.harvard.edu/plink/">http://zzz.bwh.harvard.edu/plink/</ext-link>) [<xref ref-type="bibr" rid="CR34">34</xref>]. We performed univariable and multivariable logistic regression analyses in order to analyse the independent contribution of each polymorphism to the occurrence of chronic HCV infection (dependent or outcome variable). The categorical independent variables included in the full multivariable model were rs12979860 and rs8099917 SNP genotypes (CC, CT, TT and TT, TG, GG, respectively) adjusted by age and gender. An interaction multiplicative term between both SNPs was also tested in order to consider their joint effect, if any. Odds Ratios (OR) and 95% confidence intervals were calculated. The analyses were performed using the IBM&#x000ae; SPSS&#x000ae; Statistics version 23 Software and R software version 3.4.0 [<xref ref-type="bibr" rid="CR35">35</xref>]. Linkage disequilibrium analysis was performed using Haploview Software [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec></sec><sec id="Sec7"><title>Results</title><sec id="Sec8"><title>Demographic characteristics of infected patients and controls</title><p id="Par20">Seventy-eight treatment-na&#x000ef;ve patients with chronic HCV infection were recruited. 61.5% were male with an average age of 46&#x000a0;years. In all cases, chronic infection was confirmed by a viral load above the limit of detection or by qualitative PCR detection. HCV genotypic analysis confirmed the prevalence of genotype 1 (57.7%) in the cohort. The control group included 92 individuals, all of which were HCV, HIV and HBV negative by serologic methods. 72.8% were male with an average age of 40&#x000a0;years. All demographic characteristics are presented in Table <xref rid="Tab1" ref-type="table">1</xref>, including the histological stages for the infected population and the viral genotypes, if previously determined. No significant difference was found in terms of gender distribution (<italic>p</italic>&#x02009;&#x02265;&#x02009;0.05). On the contrary, the difference in age between groups was statistically significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). The stage of liver disease according to Metavir score was available in 49 of the 78 infected patients. Cirrhosis (stage 3 and 4) was observed in 29 (59.2%) of them (Table <xref rid="Tab1" ref-type="table">1</xref>).</p></sec><sec id="Sec9"><title>SNPs rs12979860 and rs8099917 genotype distribution in non-infected individuals and in HCV-infected patients</title><p id="Par21">Several reports establish a strong link between SNPs rs12979860 and rs8099917 with the response to peg-IFN-&#x003b1;/RBV treatment for HCV genotype 1 infected patients [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. To date no study exists that shows the distribution of these polymorphisms within the Uruguayan population despite the fact that HCV genotype 1 is confirmed as the most prevalent viral genotype in the country (Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR40">40</xref>]. To gain information regarding the distribution of IL28B SNPs among the Uruguayan population the genomic DNA from 92 non-infected, non-related individuals were analysed. The distribution of rs12979860 genotypes within this control group were 45.7% CC, 42.4% CT and 11.9% TT, while for the rs8099917 they were 60.9% TT, 33.7% GT and 5.4% GG (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). SNP rs12979860 and rs8099917 showed to be in Hardy-Weinberg equilibrium (&#x003c7;<sup>2</sup> tests, <italic>p&#x02009;&#x02265;</italic>&#x000a0;0.05) in the control group, which allowed us to proceed with the genotype distribution comparison in both populations. Next we sought to establish the distribution of IL28B polymorphisms within a Uruguayan cohort of 78 treated na&#x000ef;ve HCV-infected patients. SNP analysis in the HCV-infected cohort revealed that the frequencies for the rs12979860 genotypes were 29.5% CC, 47.4% CT and 23.1% TT, while frequencies for the rs8099917 TT, GT and GG genotypes were 57.7%, 28.2% and 14.1%, respectively (Fig. <xref rid="Fig1" ref-type="fig">1</xref> and Table <xref rid="Tab2" ref-type="table">2</xref>). Under both a codominant as well as a dominant model, the genotype distribution corresponding to rs12979860 (CC, CT, TT) between the non-infected control group and the HCV-infected cohort (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>) evidenced to be statistically significant (<italic>p</italic>&#x002c2;0.05) even after multiple test correction, with a higher prevalence of the favourable genotype (CC) within the control group (Table <xref rid="Tab2" ref-type="table">2</xref>). A similar analysis was done for rs8099917 genotype distributions; however no statistically significant differences between both cohorts were found (Fig. <xref rid="Fig1" ref-type="fig">1b</xref> and&#x000a0;Table <xref rid="Tab2" ref-type="table">2</xref>). The allelic frequencies between both populations also showed to be statistically different only for rs12979860 (Fig. <xref rid="Fig1" ref-type="fig">1c</xref> and&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>). No association was observed between IL28B genotype and other variables such as gender, HCV genotype or liver fibrosis stage (Additional&#x000a0;files&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref> and <xref rid="MOESM2" ref-type="media">2</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>IL28B polymorphisms in a Uruguayan HCV-infected population (<italic>n</italic>&#x02009;=&#x02009;78) and a Uruguayan uninfected population (<italic>n</italic>&#x02009;=&#x02009;92). <bold>a</bold> SNP rs12979860 genotype distribution, where CC is considered as the good genotype and CT/TT as the unfavourable genotypes. The difference between groups is statistically significant (&#x003c7;<sup>2</sup> test - codominant model, <italic>p</italic>&#x02009;=&#x02009;0.045). <bold>b</bold> SNP rs8099917 genotype distribution, where TT is considered as the good genotype and TG/GG as the unfavourable genotypes. <bold>c</bold> SNP rs12979860 allelic distribution. The distribution between both populations is statistically significant (&#x003c7;<sup>2</sup> test, <italic>p</italic>&#x02009;=&#x02009;0.010). <bold>d</bold> SNP rs8099917 allelic distribution</p></caption><graphic xlink:href="12985_2018_946_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Genotype frequency of SNP rs12979860 and rs8099917 in both populations</p></caption><table frame="hsides" rules="groups"><thead><tr><th>IL28B SNP</th><th>HCV-infected population (<italic>n</italic>&#x02009;=&#x02009;78)</th><th>Uninfected population (<italic>n</italic>&#x02009;=&#x02009;92)</th><th>Statistical test and value</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>
<italic>rs12979860, n (%)</italic>
</td><td/><td/><td>&#x003c7;<sup>2</sup><sub>cd</sub> 6.185</td><td>0.045*</td></tr><tr><td>&#x02003;CC</td><td>23 (29.5)</td><td>42 (45.7)</td><td/><td/></tr><tr><td>&#x02003;CT</td><td>37 (47.4)</td><td>39 (42.4)</td><td/><td/></tr><tr><td>&#x02003;TT</td><td>18 (23.1)</td><td>11 (11.9)</td><td/><td/></tr><tr><td>&#x02003;CT&#x02009;+&#x02009;TT d</td><td>55 (70.5)</td><td>50 (54.3)</td><td>&#x003c7;<sup>2</sup><sub>d</sub> 4.671</td><td>0.031*</td></tr><tr><td>&#x02003;CC&#x02009;+&#x02009;CT r</td><td>60 (76.9)</td><td>81 (88.0)</td><td>&#x003c7;<sup>2</sup><sub>r</sub> 3.689</td><td>0.055</td></tr><tr><td>
<italic>rs 8,099,917, n(%)</italic>
</td><td/><td/><td>&#x003c7;<sup>2</sup><sub>cd</sub> 3.850</td><td>0.146</td></tr><tr><td>&#x02003;TT</td><td>45 (57.7)</td><td>56 (60.9)</td><td/><td/></tr><tr><td>&#x02003;TG</td><td>22 (28.2)</td><td>31 (33.7)</td><td/><td/></tr><tr><td>&#x02003;GG</td><td>11 (14.1)</td><td>5 (5.4)</td><td/><td/></tr><tr><td>TG&#x02009;+&#x02009;GG d</td><td>33 (42.3)</td><td>36 (39.1)</td><td>&#x003c7;<sup>2</sup><sub>d</sub> 0.177</td><td>0.674</td></tr><tr><td>TT&#x02009;+&#x02009;TG r</td><td>67 (85.9)</td><td>87 (94.6)</td><td>&#x003c7;<sup>2</sup><sub>r</sub> 3.720</td><td>0.054</td></tr></tbody></table><table-wrap-foot><p>&#x003c7;<sup>2</sup> Chi-square test; cd&#x02009;=&#x02009;Codominant model; d&#x02009;=&#x02009;Dominant model; r&#x02009;=&#x02009;Recessive model; *<italic>p</italic> &#x0003c; 0.05</p></table-wrap-foot></table-wrap></p><p id="Par22">Of the 42 HCV-infected patients who underwent and finished IFN-&#x003b1;/RBV treatment, 17 achieved SVR, whereas 25 did not (3 NR and 21 relapsers). Among those who responded favourably, 23.5% carried the rs12979860 good-response genotype (CC) while 58.8% carried the rs8099917 favourable genotype (TT). Among non-responder and relapser patients, these frequencies were lower (20.0% - CC and 48.0% - TT, respectively). Nevertheless, chi-squared and Fischer&#x02019;s exact tests did not evidence statistically significant differences in distributions of IL28B genotypes between both groups.</p><p id="Par23">Next we sought to determine the contribution of IL28B SNPs to the occurrence of chronic HCV-infection by performing logistic regression analyses (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). The results of univariable and multivariable (adjusted by age and sex) models suggest that when rs8099917 genotype is constant, individuals carrying rs12979860 unfavourable genotypes TT and CT on average have a 5.783 (TT) and 3.086 (CT) fold higher likelihood (adjusted OR<sub>TT</sub>&#x02009;=&#x02009;5.783, <italic>p</italic>&#x02009;=&#x02009;0.023; adjusted OR<sub>CT</sub>&#x02009;=&#x02009;3.086, <italic>p</italic>&#x02009;=&#x02009;0.015) of developing a chronic infection upon infection with HCV when compared to individuals hosting the favourable genotype (CC). Noteworthy, all individuals homozygous for the favourable allele of rs12979860 (CC) also carried the favourable genotype of rs8099917 (TT). It should be noted that no interaction between the SNPs was evidenced, as revealed by a non-converging model. In addition, rs12979860 &#x02013; TT/CT as well as age were found to be associated with a higher chance of chronic infection occurrence in both univariable and multivariable models.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Logistic regression of each polymorphism in cases (chronic HCV-infected patients) versus controls (uninfected individuals)</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Factor</th><th colspan="2">Univariable Models</th><th colspan="4">Multivariable Model</th></tr><tr><th>Estimate</th><th>OR (95% CI)</th><th><italic>p</italic> value</th><th>Estimate</th><th>OR (95% CI)</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="7">
<italic>rs12979860</italic>
</td></tr><tr><td>&#x02003;CC</td><td>NA</td><td>1</td><td/><td>NA</td><td>1</td><td/></tr><tr><td>&#x02003;TT</td><td>1.095</td><td>2.988 (1.208&#x02013;7.395)</td><td>0.018*</td><td>1.755</td><td>5.783 (1.279&#x02013;26.142)</td><td>0.023*</td></tr><tr><td>&#x02003;TC</td><td>0.550</td><td>1.732 (0.879&#x02013;3.415)</td><td>0.113</td><td>1.127</td><td>3.086 (1.247&#x02013;7.642)</td><td>0.015*</td></tr><tr><td colspan="7">
<italic>rs 8,099,917</italic>
</td></tr><tr><td>&#x02003;TT</td><td>NA</td><td>1</td><td/><td>NA</td><td>1</td><td/></tr><tr><td>&#x02003;GG</td><td>1.007</td><td>2.738 (0.886&#x02013;8.454)</td><td>0.080</td><td>&#x02212;0.240</td><td>0.787 (0.141&#x02013;4.375)</td><td>0.784</td></tr><tr><td>&#x02003;TG</td><td>&#x02212;0.124</td><td>0.883 (0.451&#x02013;1.730)</td><td>0.717</td><td>&#x02212;0.672</td><td>0.511 (0.197&#x02013;1.325)</td><td>0.167</td></tr><tr><td>
<italic>Age</italic>
</td><td>0.051</td><td>1.052 (1.023&#x02013;1.082)</td><td>&#x0003c;0.001*</td><td>0.036</td><td>1.037 (1.008&#x02013;1.067)</td><td>0.012*</td></tr><tr><td>
<italic>Gender</italic>
</td><td>&#x02212;0.516</td><td>0.597 (0.312&#x02013;1.141)</td><td>0.118</td><td>0.546</td><td>1.727 (0.843&#x02013;3.537)</td><td>0.135</td></tr></tbody></table><table-wrap-foot><p>Odds ratio were constructed considering favourable genotypes (rs12979860-CC and rs 8,099,917-TT) as reference. OR: Odds ratio; CI: Confidence Interval; *<italic>p</italic> &#x0003c; 0.05</p></table-wrap-foot></table-wrap></p><p id="Par24">The results of the genotype distribution comparisons as well as the logistic regression are supported by Haploview analyses showing that both SNPs are in weak Linkage Disequilibrium in both of the studied populations (controls: r<sup>2</sup>&#x02009;=&#x02009;0.57; infected-patients: r<sup>2</sup>&#x02009;=&#x02009;0.37; both: r<sup>2</sup>&#x02009;=&#x02009;0.48). This observation also indicates that for the studied population of HCV-infected patients the association between IL28B SNPs and development of HCV chronicity is primarily driven by only one of the evaluated polymorphisms.</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par25">Infections with HCV have become a major cause of liver cancer and one of the most common indications for liver transplantation [<xref ref-type="bibr" rid="CR1">1</xref>]. In Uruguay the combination of peg-IFN-&#x003b1; plus RBV is still the main option for HCV treatment, despite the fact that HCV genotype 1 is the predominant genotype among the infected patients in Uruguay [<xref ref-type="bibr" rid="CR40">40</xref>]. This, in addition to the high cost of the new direct-acting therapies, highlight the relevance of searching for new indicators of response to antiviral therapy in the Uruguayan population in order to provide information that could be a useful guide for clinicians, enabling them to select a more patient-personalised anti-HCV therapy.</p><p id="Par26">Many host factors have been associated with HCV-treatment outcome, among which, specific single-nucleotide polymorphisms (SNPs) located near the interleukin 28B (IL28B) gene have been shown to exhibit a significant relationship with both spontaneous virus clearance and response to peg-IFN-&#x003b1;/RBV treatment [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. In this context, and considering that no information on IL28B SNPs genotype distribution was known for Uruguay, we were interested in evaluating the frequency of IL28B rs12979860 and rs8099917 in a cohort of Uruguayan individuals (HCV-infected as well as uninfected). With this aim, 92 healthy individuals and 78 HCV-infected patients were studied.</p><p id="Par27">In full agreement with what others have reported [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>], the frequency of the IL28B rs12979860 favourable genotype (CC), which strongly predicts spontaneous clearance of HCV infection, was less prevalent among the studied HCV-infected population than within the non-infected individuals. This differential genotypic distribution was statistically significant (<italic>p</italic>&#x002c2;0.05) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). This bias toward the less favourable genotype for rs12979860 is most probably associated to the way HCV-infected patients were selected for the study as all were recruited in a hospital setting. No significant differences between the frequencies of the protective rs8099917-TT genotype in general population and the studied HCV-infected patients were observed. The unfavourable homozygous genotypes were found at a low frequency in both populations under study (rs12979860-TT 23.1% vs 11.9% and rs8099917-GG 14.1% vs 5.4%, in the infected and control group, respectively). Given that a higher prevalence of favourable rs12979860 genotype has been found among healthy individuals when compared to HCV-infected patients [<xref ref-type="bibr" rid="CR41">41</xref>], it is plausible that our results support the notion of a protective effect of IL28B &#x0201c;good&#x0201d; response genotype within the Uruguayan population, as has been previously suggested by others [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR44">44</xref>].</p><p id="Par28">Additionally, by means of logistic regression analyses we show that individuals carrying rs12979860-TT or CT genotypes have a higher likelihood of developing chronic hepatitis upon infection with HCV, when compared to CC carriers, when the rs8099917 genotype is constant (Table <xref rid="Tab3" ref-type="table">3</xref>). Therefore, our results suggest that within the Uruguayan population rs12979860 might be a better predictor than rs8099917, at least in terms of occurrence of chronic HCV infection. This is also in agreement with the fact that these SNPs seem to be in weak linkage disequilibrium, which indicates that only one of them might be associated with development of chronicity in the studied Uruguayan cohort.</p><p id="Par29">An interesting finding of this work is that it shows that the genotype frequencies in Uruguay seem to fall in the same ranges as those found in other countries (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>), this with the exception of Asian countries where the prevalence of protective genotypes were found to be higher [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Although the allelic frequencies of both SNPs in the control group fall in the range of the frequencies reported for different European populations [<xref ref-type="bibr" rid="CR24">24</xref>], the distribution of genotypes in the Uruguayan population seems to be more similar to the frequencies reported in Brazil [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>] and the rs12979860-CC prevalence among infected patients (29.5%) resembles the one reported for Hispanics, rather than Caucasians (Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>). This observation raises important questions regarding the Uruguayan genetic background and ethnicity. Uruguay has no Native American or African-descendant communities and until the 1980s its national identity was regarded as almost strictly Caucasian [<xref ref-type="bibr" rid="CR32">32</xref>]. More recently, however, several reports based both on classical markers as well as nuclear DNA analysis have revealed that the Uruguayan population has a small but important African and Native American ancestry contribution (see [<xref ref-type="bibr" rid="CR32">32</xref>] for a detailed review). Thus, it is tempting to speculate that it is this previously non-considered ethnic contribution that would explains why the SNPs frequencies within the Uruguayan population closely resemble those of admixed rather than a Caucasian population.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Il28B favourable genotype prevalence reported in different countries</p></caption><table frame="hsides" rules="groups"><thead><tr><th>IL28B SNP</th><th>Uninfected population % (<italic>n</italic>)</th><th>HCV-infected population % (<italic>n</italic>)</th><th>Country</th><th>Year of publication</th></tr></thead><tbody><tr><td colspan="5">
<italic>Rs12979860; CC</italic>
</td></tr><tr><td/><td>44.7 (378)</td><td>45.6 (283)</td><td>Spain</td><td>2010 [<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr><td/><td>45.1 (122)</td><td>26.9 (108)</td><td>Egypt</td><td>2015 [<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td/><td>44.6 (92)</td><td>32.1 (136)</td><td>Turkey</td><td>2015 [<xref ref-type="bibr" rid="CR41">41</xref>]</td></tr><tr><td/><td>43.7 (142)</td><td>38.0 (921) &#x02013; 42.0 (100)</td><td>Iran</td><td>2012 [<xref ref-type="bibr" rid="CR49">49</xref>], 2016 [<xref ref-type="bibr" rid="CR50">50</xref>]</td></tr><tr><td/><td>86.9 (320)</td><td>88.6 (297)</td><td>China</td><td>2015 [<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td/><td>ND</td><td>24.1 (83)</td><td>Mexico</td><td>2012 [<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td/><td>35.7 (185)</td><td>ND</td><td>Bolivia</td><td>2014 [<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td/><td>38.1 (76)</td><td>ND</td><td>Peru</td><td>2014 [<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td/><td>38.8 (98)</td><td>ND</td><td>Paraguay</td><td>2014 [<xref ref-type="bibr" rid="CR26">26</xref>]</td></tr><tr><td/><td>37.0 (405)</td><td>20.2 (99)</td><td>Chile</td><td>2013 [<xref ref-type="bibr" rid="CR27">27</xref>], 2011 [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td/><td>51.6 (991)</td><td>18.4 (102)</td><td>Argentina</td><td>2014 [<xref ref-type="bibr" rid="CR26">26</xref>], 2011 [<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td/><td>47.4 (190)</td><td>24.0 (221) &#x02013; 30.9 (175)</td><td>Brazil</td><td>2012 [<xref ref-type="bibr" rid="CR31">31</xref>], 2015 [<xref ref-type="bibr" rid="CR30">30</xref>]</td></tr><tr><td/><td>45.6 (92)</td><td>29.5 (78)</td><td>Uruguay</td><td>This study</td></tr><tr><td colspan="5">
<italic>rs8099917; TT</italic>
</td></tr><tr><td/><td>64.1 (142)</td><td>58.3 (921)</td><td>Iran</td><td>2012 [<xref ref-type="bibr" rid="CR49">49</xref>]</td></tr><tr><td/><td>88.7 (320)</td><td>89.6 (297)</td><td>China</td><td>2015 [<xref ref-type="bibr" rid="CR51">51</xref>]</td></tr><tr><td/><td>89.3 (197)</td><td>81.0 (400)</td><td>Taiwan</td><td>2016 [<xref ref-type="bibr" rid="CR45">45</xref>]</td></tr><tr><td/><td>ND</td><td>27.5 (80)</td><td>Mexico</td><td>2012 [<xref ref-type="bibr" rid="CR25">25</xref>]</td></tr><tr><td/><td>46.9 (405)</td><td>29.3 (99)</td><td>Chile</td><td>2013 [<xref ref-type="bibr" rid="CR27">27</xref>], 2011 [<xref ref-type="bibr" rid="CR28">28</xref>]</td></tr><tr><td/><td>ND</td><td>40.2 (102)</td><td>Argentina</td><td>2011 [<xref ref-type="bibr" rid="CR29">29</xref>]</td></tr><tr><td/><td>67.8 (199)</td><td>54.2 (177) &#x02013; 63.1 (222)</td><td>Brazil</td><td>2015 [<xref ref-type="bibr" rid="CR30">30</xref>], 2012 [<xref ref-type="bibr" rid="CR31">31</xref>]</td></tr><tr><td/><td>60.9 (92)</td><td>57.7 (78)</td><td>Uruguay</td><td>This study</td></tr></tbody></table></table-wrap><table-wrap id="Tab5"><label>Table 5</label><caption><p>Rs12979860 favourable genotype (CC) prevalence reported according to ethnicity in HCV-infected patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>HCV-infected population % (<italic>n</italic>)</th><th>Ethnicity</th><th>Year of publication</th></tr></thead><tbody><tr><td>33.3 (2582) &#x02013; 37.2 (1171)</td><td>Caucasians</td><td>2016 [<xref ref-type="bibr" rid="CR52">52</xref>], 2010 [<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td>22.9 (105) &#x02013; 29.3 (116)</td><td>Hispanics</td><td>2016 [<xref ref-type="bibr" rid="CR52">52</xref>], 2010 [<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td>10.4 (48) &#x02013; 14.0 (300)</td><td>African Americans/Black</td><td>2016 [<xref ref-type="bibr" rid="CR52">52</xref>], 2010 [<xref ref-type="bibr" rid="CR13">13</xref>]</td></tr><tr><td>49.2 (181)</td><td>Asian</td><td>2016 [<xref ref-type="bibr" rid="CR52">52</xref>]</td></tr></tbody></table></table-wrap></p><p id="Par30">Several reports from different countries and regions have found associations between favourable genotypes of IL28B SNPs and SVR [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR46">46</xref>], regretfully we did not find evidence which supports this link in our Uruguayan population. Differences in SNPs genotype distributions between SVR and NR/R patients were not statistically significant (chi-squared and Fisher&#x02019;s exact tests considering the three modes of inheritance: codominant, dominant and recessive). This might be attributable to the small number of patients included in this study that had finished their therapy by the time of writing this report (<italic>n</italic>&#x02009;=&#x02009;42) which accounts for 53.8% of all HCV-infected patients enrolled. In addition, of those 42 HCV-infected individuals that had completed their dual treatment, 17 achieved SVR while 25 were either non-responders or relapsers (NR/R). Of those who achieved SVR, 23.5% (n&#x02009;=&#x02009;4/17) harboured the favourable IL28B genotype (rs12979860-CC), whereas only 20.0% of the NR/R patients had the favourable genotype (<italic>n</italic>&#x02009;=&#x02009;5/25). These results suggest a slight trend towards a higher frequency of &#x0201c;good&#x0201d; response genotypes in responder patients. This tendency has also been observed in other populations in Latin America where the frequency of CC-carriers among the NR patients (2% in Chile [<xref ref-type="bibr" rid="CR28">28</xref>] and 20% in Mexico [<xref ref-type="bibr" rid="CR25">25</xref>]) seems to be lower than among SVR patients. The small number of patients corresponding to each group (SVR or NR/R) might explain why we were not able to confirm the association between IL28B genotypes and response to therapy. Despite Heo et al. (2014) [<xref ref-type="bibr" rid="CR47">47</xref>] also reported no association even when including a larger number of patients (<italic>n</italic>&#x02009;=&#x02009;156), the ethnic disparities between Uruguayan and Korean populations does not allow us to confirm our findings. A limitation of our analyses, however, is that due to the limited number of patients, association studies were performed without taking into account the viral genotype. In this respect, some authors report no association between IL28B SNPs and SVR in patients infected with HCV genotype 3 [<xref ref-type="bibr" rid="CR48">48</xref>]. This fact might have biased our results since we included both HCV genotype 1 and 3 infected patients.</p><p id="Par31">As mentioned before, despite the fact that some of the new treatment regimens including DAAs have been approved for use by Uruguayan national authorities, their costs are not always covered by our health system, making them unaffordable for most of the population. Therefore, we believe it would still be relevant for our country to use hosts genotype data as a predictor of response to HCV-treatment. Furthermore, IL28B genotype seems to be also informative when new DAAs are used, both in the context of protease inhibitors combination therapy [<xref ref-type="bibr" rid="CR15">15</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>] as well as in IFN-free regimens with sofosbuvir (polymerase inhibitor) and ledipasvir (NS5A inhibitor) [<xref ref-type="bibr" rid="CR20">20</xref>]. Therefore, it is feasible to propose that IL28B genotyping could be a powerful tool use in Uruguay to predict the best personalised anti HCV-treatment in the upcoming years.</p></sec><sec id="Sec11"><title>Conclusions</title><p id="Par32">In conclusion, the present study shows that the favourable genotypes rs12979860-CC and rs8099917-TT were present in 29.5% and 57.7% of the Uruguayan population infected with HCV, respectively. As expected, the prevalence within the non-infected population was higher (45.6% for rs12979860 and 60.8% for rs8099917). Only IL28B rs12979860-CT and TT genotypes seem to contribute to the occurrence of chronic HCV infection in the cohort of Uruguayan population studied. Considering that a slight trend towards a higher frequency of &#x0201c;good&#x0201d; response genotypes was observed in responder patients, we believe that IL28B rs12979860 genotyping could be a useful tool for predicting different therapies outcome, including in the DAA era. It is worth mentioning that this study also found that allele and genotype frequencies closely resemble those of an admixed population rather than a uniformly European-descendant one, which is in agreement with previous studies on non-Caucasian ancestry contribution to Uruguayan population [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec12"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12985_2018_946_MOESM1_ESM.docx"><label>Additional file 1:</label><caption><p>SNP rs12979860 genotypes according to infected patient characteristics. (DOCX 15 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12985_2018_946_MOESM2_ESM.docx"><label>Additional file 2:</label><caption><p>SNP rs8099917 genotypes according to infected patient characteristics. (DOCX 15 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>DAA</term><def><p id="Par5">Direct-acting Agent</p></def></def-item><def-item><term>HCV</term><def><p id="Par6">Hepatitis C Virus</p></def></def-item><def-item><term>IL28B</term><def><p id="Par7">Interleuquin 28B</p></def></def-item><def-item><term>Peg-IFN-&#x003b1;</term><def><p id="Par8">pegylated interferon alpha</p></def></def-item><def-item><term>RBV</term><def><p id="Par9">Ribavirin</p></def></def-item><def-item><term>SNP</term><def><p id="Par10">Single-nucleotide Polymorphism</p></def></def-item><def-item><term>SVR</term><def><p id="Par11">Sustained Virological Response</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (10.1186/s12985-018-0946-2) contains supplementary material, which is available to authorized users.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank Dr. Lilia L&#x000f3;pez for her assistance on recruiting healthy individuals for this study.</p><sec id="FPar1"><title>Funding</title><p id="Par33">This work was supported by Agencia Nacional de Investigaci&#x000f3;n e Innovaci&#x000f3;n (ANII), PEDECIBA, Comisi&#x000f3;n Acad&#x000e9;mica de Posgrados, Cl&#x000ed;nica de Gastroenterolog&#x000ed;a-Hospital de Cl&#x000ed;nicas, Universidad de la Rep&#x000fa;blica (UdelaR) and Comisi&#x000f3;n Sectorial de Investigaci&#x000f3;n Cient&#x000ed;fica (CSIC), UdelaR, Uruguay.&#x000a0;Work conducted by NE in Chile was funded by CONICYT-PIA ACT1408, and projectP09/016-F&#x02013;ICM.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par34">The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>NE, DC, NH and PM conceived the study. NE, DC, JA, MLL, NH and PM designed the analysis. AC and CB contributed to data collection. NE, DC, PS and PL performed the SNPs studies. NE, DC, VC and NH performed statistical analyses. JC, MLL and JA contribute to the discussion of all results obtained in this work. NE, DC, NH and PM wrote the paper. All authors reviewed and approved the final manuscript. NE, DC, NH and PM were responsible for the integrity of the work as a whole.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par35">The study was conducted according to national and international ethical guidelines (good clinical practice, Nuremberg statements, Declaration of Helsinki) and local regulatory rules (Mercosur Standards/GMC/RES No. 129/96). The protocol was approved by the Ethics Committee of the Hospital de Cl&#x000ed;nicas on October 24th (2014) and all patients gave written informed consent. Access to personal information was restricted to the medical doctors. The genetic information extracted from the samples was used exclusively for the purposes of this study.</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par36">Not applicable.</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par37">The authors declare that they have no competing interests.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par38">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">2017 GHR. Geneva: World Health Organization. Geneva; 2017. licence: CC BY-NC-SA 3.0 IGO.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernandez</surname><given-names>N</given-names></name><name><surname>Mescia</surname><given-names>G</given-names></name><name><surname>Pollio</surname><given-names>C</given-names></name><name><surname>Robaina</surname><given-names>G</given-names></name><name><surname>Quintana</surname><given-names>L</given-names></name><name><surname>Bianchi</surname><given-names>C</given-names></name></person-group><article-title>Effectiveness of pegylated interferon alfa 2a and ribavirin for chronic hepatitis C in clinical practice</article-title><source>Acta Gastroenterol Latinoam</source><year>2010</year><volume>40</volume><fpage>117</fpage><lpage>121</lpage><?supplied-pmid 20645558?><pub-id pub-id-type="pmid">20645558</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>McHutchison</surname><given-names>JG</given-names></name><name><surname>Gordon</surname><given-names>SC</given-names></name><name><surname>Rustgi</surname><given-names>VK</given-names></name><name><surname>Shiffman</surname><given-names>M</given-names></name><name><surname>Reindollar</surname><given-names>R</given-names></name><etal/></person-group><article-title>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial</article-title><source>Lancet (London, England)</source><year>2001</year><volume>358</volume><fpage>958</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(01)06102-5</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hadziyannis</surname><given-names>SJ</given-names></name><name><surname>Sette</surname><given-names>H</given-names></name><name><surname>Morgan</surname><given-names>TR</given-names></name><name><surname>Balan</surname><given-names>V</given-names></name><name><surname>Diago</surname><given-names>M</given-names></name><name><surname>Marcellin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose</article-title><source>Ann Intern Med</source><year>2004</year><volume>140</volume><fpage>346</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-140-5-200403020-00010</pub-id><?supplied-pmid 14996676?><pub-id pub-id-type="pmid">14996676</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Cornberg</surname><given-names>M</given-names></name></person-group><article-title>Treating viral hepatitis C: efficacy, side effects, and complications</article-title><source>Gut</source><year>2006</year><volume>55</volume><issue>9</issue><fpage>1350</fpage><pub-id pub-id-type="doi">10.1136/gut.2005.076646</pub-id><?supplied-pmid 16905701?><pub-id pub-id-type="pmid">16905701</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cornberg</surname><given-names>M</given-names></name><name><surname>Hardtke</surname><given-names>S</given-names></name><name><surname>Port</surname><given-names>K</given-names></name><name><surname>Manns</surname><given-names>MP</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name><name><surname>Standard</surname><given-names>HC</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Mauss</surname><given-names>S</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Rockstroh</surname><given-names>J</given-names></name><name><surname>Sarrazin</surname><given-names>C</given-names></name><name><surname>Wedemeyer</surname><given-names>H</given-names></name></person-group><article-title>Of care</article-title><source>Short guide to hepatitis C. Flying Publisher</source><year>2012</year><fpage>34</fpage><lpage>57</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>D</given-names></name><name><surname>Fellay</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name><name><surname>Simon</surname><given-names>JS</given-names></name><name><surname>Shianna</surname><given-names>KV</given-names></name><name><surname>Urban</surname><given-names>TJ</given-names></name><etal/></person-group><article-title>Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance</article-title><source>Nature</source><year>2009</year><volume>461</volume><fpage>399</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nature08309</pub-id><?supplied-pmid 19684573?><pub-id pub-id-type="pmid">19684573</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suppiah</surname><given-names>V</given-names></name><name><surname>Moldovan</surname><given-names>M</given-names></name><name><surname>Ahlenstiel</surname><given-names>G</given-names></name><name><surname>Berg</surname><given-names>T</given-names></name><name><surname>Weltman</surname><given-names>M</given-names></name><name><surname>Abate</surname><given-names>ML</given-names></name><etal/></person-group><article-title>IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>1100</fpage><lpage>1104</lpage><pub-id pub-id-type="doi">10.1038/ng.447</pub-id><?supplied-pmid 19749758?><pub-id pub-id-type="pmid">19749758</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Nishida</surname><given-names>N</given-names></name><name><surname>Sugiyama</surname><given-names>M</given-names></name><name><surname>Kurosaki</surname><given-names>M</given-names></name><name><surname>Matsuura</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>N</given-names></name><etal/></person-group><article-title>Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C</article-title><source>Nat Genet</source><year>2009</year><volume>41</volume><fpage>1105</fpage><lpage>1109</lpage><pub-id pub-id-type="doi">10.1038/ng.449</pub-id><?supplied-pmid 19749757?><pub-id pub-id-type="pmid">19749757</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Thio</surname><given-names>CL</given-names></name><name><surname>Martin</surname><given-names>MP</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>D</given-names></name><name><surname>O&#x02019;Huigin</surname><given-names>C</given-names></name><etal/></person-group><article-title>Genetic variation in IL28B and spontaneous clearance of hepatitis C virus</article-title><source>Nature</source><year>2009</year><volume>461</volume><fpage>798</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1038/nature08463</pub-id><?supplied-pmid 19759533?><pub-id pub-id-type="pmid">19759533</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scherzer</surname><given-names>TM</given-names></name><name><surname>St&#x000e4;ttermayer</surname><given-names>AF</given-names></name><name><surname>Strasser</surname><given-names>M</given-names></name><name><surname>Laferl</surname><given-names>H</given-names></name><name><surname>Maieron</surname><given-names>A</given-names></name><name><surname>Stauber</surname><given-names>R</given-names></name><etal/></person-group><article-title>Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40KD)/ribavirin</article-title><source>Hepatology</source><year>2011</year><volume>54</volume><fpage>1518</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1002/hep.24546</pub-id><?supplied-pmid 22006276?><pub-id pub-id-type="pmid">22006276</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauch</surname><given-names>A</given-names></name><name><surname>Kutalik</surname><given-names>Z</given-names></name><name><surname>Descombes</surname><given-names>P</given-names></name><name><surname>Cai</surname><given-names>T</given-names></name><name><surname>Di Iulio</surname><given-names>J</given-names></name><name><surname>Mueller</surname><given-names>T</given-names></name><etal/></person-group><article-title>Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study</article-title><source>Gastroenterology</source><year>2010</year><volume>138</volume><fpage>1338</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.12.056</pub-id><?supplied-pmid 20060832?><pub-id pub-id-type="pmid">20060832</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained Virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120-9.e18. 10.1053/j.gastro.2010.04.013.</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139:827.e1&#x02013;827.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>JA</given-names></name><name><surname>Desmond</surname><given-names>PV</given-names></name><name><surname>Thompson</surname><given-names>AJ</given-names></name></person-group><article-title>Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection?</article-title><source>J Viral Hepat</source><year>2012</year><volume>19</volume><fpage>677</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1111/jvh.12003</pub-id><?supplied-pmid 22967098?><pub-id pub-id-type="pmid">22967098</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calisti</surname><given-names>G</given-names></name><name><surname>Tavares</surname><given-names>A</given-names></name><name><surname>Macartney</surname><given-names>MJ</given-names></name><name><surname>McCormick</surname><given-names>A</given-names></name><name><surname>Labbett</surname><given-names>W</given-names></name><name><surname>Jacobs</surname><given-names>M</given-names></name><etal/></person-group><article-title>IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment na&#x000ef;ve and treatment-experienced patients other than prior partial- and null-responders</article-title><source>Spring</source><year>2015</year><volume>4</volume><fpage>357</fpage><pub-id pub-id-type="doi">10.1186/s40064-015-1137-x</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>About</surname><given-names>F</given-names></name><name><surname>Oudot-Mellakh</surname><given-names>T</given-names></name><name><surname>Niay</surname><given-names>J</given-names></name><name><surname>Rabi&#x000e9;ga</surname><given-names>P</given-names></name><name><surname>Pedergnana</surname><given-names>V</given-names></name><name><surname>Duffy</surname><given-names>D</given-names></name><etal/></person-group><article-title>Impact of IL28B, APOH and ITPA polymorphisms on efficacy and safety of TVRor BOC-based triple therapy in treatment-experienced HCV-1 patients with compensated cirrhosis from the ANRS CO20-CUPIC study</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1371/journal.pone.0145105</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barreiro</surname><given-names>P</given-names></name><name><surname>Vispo</surname><given-names>E</given-names></name><name><surname>Poveda</surname><given-names>E</given-names></name><name><surname>Fern&#x000e1;ndez-Montero</surname><given-names>JV</given-names></name><name><surname>Soriano</surname><given-names>V</given-names></name></person-group><article-title>Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the liver</article-title><source>Clin Infect Dis</source><year>2013</year><volume>56</volume><fpage>560</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1093/cid/cis915</pub-id><?supplied-pmid 23090932?><pub-id pub-id-type="pmid">23090932</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Offizi</surname><given-names>G</given-names></name><name><surname>Camm&#x000e0;</surname><given-names>C</given-names></name><name><surname>Taibi</surname><given-names>C</given-names></name><name><surname>Schlag</surname><given-names>M</given-names></name><name><surname>Palma</surname><given-names>M</given-names></name><name><surname>Demasi</surname><given-names>R</given-names></name><etal/></person-group><article-title>Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection</article-title><source>New Microbiol</source><year>2017</year><volume>40</volume><fpage>19</fpage><lpage>26</lpage><?supplied-pmid 28072888?><pub-id pub-id-type="pmid">28072888</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akuta</surname><given-names>N</given-names></name><name><surname>Sezaki</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>F</given-names></name><name><surname>Fujiyama</surname><given-names>S</given-names></name><name><surname>Kawamura</surname><given-names>Y</given-names></name><name><surname>Hosaka</surname><given-names>T</given-names></name><etal/></person-group><article-title>Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan</article-title><source>J Med Virol</source><year>2017</year><volume>89</volume><fpage>284</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1002/jmv.24617</pub-id><?supplied-pmid 27357737?><pub-id pub-id-type="pmid">27357737</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Astemborski</surname><given-names>J</given-names></name><name><surname>Rai</surname><given-names>RM</given-names></name><name><surname>Anania</surname><given-names>FA</given-names></name><name><surname>Schaeffer</surname><given-names>M</given-names></name><name><surname>Galai</surname><given-names>N</given-names></name><etal/></person-group><article-title>The natural history of hepatitis C virus infection: host, viral, and environmental factors</article-title><source>JAMA</source><year>2000</year><volume>284</volume><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.1001/jama.284.4.450</pub-id><?supplied-pmid 10904508?><pub-id pub-id-type="pmid">10904508</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muir a</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>K-Q</given-names></name><name><surname>Gordon</surname><given-names>SC</given-names></name><name><surname>Koury</surname><given-names>K</given-names></name><name><surname>Boparai</surname><given-names>N</given-names></name><name><surname>Noviello</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hepatitis C treatment among racial and ethnic groups in the IDEAL trial</article-title><source>J Viral Hepat</source><year>2011</year><volume>18</volume><fpage>e134</fpage><lpage>e143</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2893.2010.01402.x</pub-id><?supplied-pmid 21108699?><pub-id pub-id-type="pmid">21108699</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinks</surname><given-names>J</given-names></name><name><surname>Hulaniuk</surname><given-names>ML</given-names></name><name><surname>Redal</surname><given-names>MA</given-names></name><name><surname>Flichman</surname><given-names>D</given-names></name></person-group><article-title>Clinical utility of pharmacogenomics in the management of hepatitis C</article-title><source>Pharmgenomics Pers Med</source><year>2014</year><volume>7</volume><fpage>339</fpage><lpage>347</lpage><?supplied-pmid 25382982?><pub-id pub-id-type="pmid">25382982</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajeevan</surname><given-names>H</given-names></name><name><surname>Soundararajan</surname><given-names>U</given-names></name><name><surname>Kidd</surname><given-names>JR</given-names></name><name><surname>Pakstis</surname><given-names>AJ</given-names></name><name><surname>Kidd</surname><given-names>KK</given-names></name></person-group><article-title>ALFRED: an allele frequency resource for research and teaching</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><issue>Database Issue</issue><fpage>D1010</fpage><lpage>D1015</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr924</pub-id><?supplied-pmid 22039151?><pub-id pub-id-type="pmid">22039151</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-G&#x000f3;mez</surname><given-names>LE</given-names></name><name><surname>Ch&#x000e1;vez-Tapia</surname><given-names>NC</given-names></name><name><surname>Burguete-Garc&#x000ed;a</surname><given-names>AI</given-names></name><name><surname>Aguilar-Olivos</surname><given-names>N</given-names></name><name><surname>Madrid-Marina</surname><given-names>V</given-names></name><name><surname>Rom&#x000e1;n-Bahena</surname><given-names>M</given-names></name><etal/></person-group><article-title>IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population</article-title><source>Ann Hepatol</source><year>2012</year><volume>11</volume><fpage>876</fpage><lpage>881</lpage><?supplied-pmid 23109451?><pub-id pub-id-type="pmid">23109451</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trinks</surname><given-names>J</given-names></name><name><surname>Hulaniuk</surname><given-names>ML</given-names></name><name><surname>Caputo</surname><given-names>M</given-names></name><name><surname>Pratx</surname><given-names>LB</given-names></name><name><surname>R&#x000e9;</surname><given-names>V</given-names></name><name><surname>Fortuny</surname><given-names>L</given-names></name><etal/></person-group><article-title>Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population</article-title><source>Pharmacogenomics J</source><year>2014</year><volume>14</volume><fpage>549</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1038/tpj.2014.20</pub-id><?supplied-pmid 24841973?><pub-id pub-id-type="pmid">24841973</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angulo</surname><given-names>J</given-names></name><name><surname>Pino</surname><given-names>K</given-names></name><name><surname>Pavez</surname><given-names>C</given-names></name><name><surname>Biel</surname><given-names>F</given-names></name><name><surname>Labb&#x000e9;</surname><given-names>P</given-names></name><name><surname>Miquel</surname><given-names>JF</given-names></name><etal/></person-group><article-title>Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients</article-title><source>J Viral Hepat</source><year>2013</year><volume>20</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1111/jvh.12076</pub-id><?supplied-pmid 23490371?><pub-id pub-id-type="pmid">23490371</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venegas</surname><given-names>M</given-names></name><name><surname>Villanueva</surname><given-names>RA</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>K</given-names></name><name><surname>Brahm</surname><given-names>J</given-names></name></person-group><article-title>IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients</article-title><source>World J Gastroenterol</source><year>2011</year><volume>17</volume><fpage>3636</fpage><lpage>3639</lpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i31.3636</pub-id><?supplied-pmid 21987611?><pub-id pub-id-type="pmid">21987611</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ridruejo</surname><given-names>E</given-names></name><name><surname>Solano</surname><given-names>&#x000c1;</given-names></name><name><surname>Marciano</surname><given-names>S</given-names></name><name><surname>Galdame</surname><given-names>O</given-names></name><name><surname>Adrover</surname><given-names>R</given-names></name><name><surname>Cocozzella</surname><given-names>D</given-names></name><etal/></person-group><article-title>Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 argentine patients treated with PEG IFN and ribavirin</article-title><source>Ann Hepatol</source><year>2011</year><volume>10</volume><fpage>452</fpage><lpage>457</lpage><?supplied-pmid 21911885?><pub-id pub-id-type="pmid">21911885</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertol</surname><given-names>BC</given-names></name><name><surname>Moreira</surname><given-names>S</given-names></name><name><surname>Garcia</surname><given-names>RFL</given-names></name><name><surname>Ferreira</surname><given-names>LE</given-names></name><name><surname>Debortoli</surname><given-names>G</given-names></name><name><surname>de Leite Pinho</surname><given-names>MS</given-names></name><etal/></person-group><article-title>IL28B gene polymorphisms in mono- and HIV-coinfected chronic hepatitis C patients</article-title><source>Front Microbiol</source><year>2015</year><volume>6</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3389/fmicb.2015.00153</pub-id><pub-id pub-id-type="pmid">25653648</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalcante</surname><given-names>LN</given-names></name><name><surname>Abe-Sandes</surname><given-names>K</given-names></name><name><surname>Angelo</surname><given-names>ALD</given-names></name><name><surname>Machado</surname><given-names>TMB</given-names></name><name><surname>Lemaire</surname><given-names>DC</given-names></name><name><surname>Mendes</surname><given-names>CMC</given-names></name><etal/></person-group><article-title>IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population</article-title><source>Liver Int</source><year>2012</year><volume>32</volume><fpage>476</fpage><lpage>486</lpage><?supplied-pmid 22098416?><pub-id pub-id-type="pmid">22098416</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salzano</surname><given-names>FM</given-names></name><name><surname>Sans</surname><given-names>M</given-names></name></person-group><article-title>Interethnic admixture and the evolution of Latin American populations</article-title><source>Genet Mol Biol</source><year>2014</year><volume>37</volume><issue>1 SUPPL. 1</issue><fpage>151</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1590/S1415-47572014000200003</pub-id><?supplied-pmid 24764751?><pub-id pub-id-type="pmid">24764751</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharafi</surname><given-names>H</given-names></name><name><surname>Pouryasin</surname><given-names>A</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Behnava</surname><given-names>B</given-names></name><name><surname>Keshvari</surname><given-names>M</given-names></name><name><surname>Mehrnoush</surname><given-names>L</given-names></name><etal/></person-group><article-title>Development and validation of a simple, rapid and inexpensive PCRRFLP method for genotyping of common IL28b polymorphisms: a useful pharmacogenetic tool for prediction of hepatitis C treatment response</article-title><source>Hepat Mon</source><year>2012</year><volume>12</volume><fpage>190</fpage><lpage>195</lpage><?supplied-pmid 22550527?><pub-id pub-id-type="pmid">22550527</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Neale</surname><given-names>B</given-names></name><name><surname>Todd-Brown</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Ferreira</surname><given-names>MAR</given-names></name><name><surname>Bender</surname><given-names>D</given-names></name><etal/></person-group><article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title><source>Am J Hum Genet</source><year>2007</year><volume>81</volume><fpage>559</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1086/519795</pub-id><?supplied-pmid 17701901?><pub-id pub-id-type="pmid">17701901</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">R Core Team. R: A Language and Environment for statistical computing. R Foundation for Statistical Computing, Vienna. 2014. <ext-link ext-link-type="uri" xlink:href="http://www.r-project.org/">http://www.r-project.org/</ext-link>.</mixed-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bth457</pub-id><?supplied-pmid 15297300?><pub-id pub-id-type="pmid">15297300</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><etal/></person-group><article-title>IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>1</fpage><lpage>8</lpage></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>JA</given-names></name><name><surname>Ramos</surname><given-names>AL</given-names></name><name><surname>Hoffmann</surname><given-names>L</given-names></name><name><surname>Perez Rde</surname><given-names>M</given-names></name><name><surname>HSM</surname><given-names>C</given-names></name><name><surname>&#x000dc;rm&#x000e9;nyi</surname><given-names>TP</given-names></name><etal/></person-group><article-title>A single nucleotide polymorphism, rs129679860, in the IL28B locus is associated with the viral kinetics and a sustained virological response in a chronic, monoinfected hepatitis C virus genotype-1 Brazilian population treated with pegylated interferon-rib</article-title><source>Mem Inst Oswaldo Cruz</source><year>2012</year><volume>107</volume><fpage>888</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1590/S0074-02762012000700008</pub-id><?supplied-pmid 23147144?><pub-id pub-id-type="pmid">23147144</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rall&#x000f3;n</surname><given-names>NI</given-names></name><name><surname>Naggie</surname><given-names>S</given-names></name><name><surname>Benito</surname><given-names>JM</given-names></name><name><surname>Medrano</surname><given-names>J</given-names></name><name><surname>Restrepo</surname><given-names>C</given-names></name><name><surname>Goldstein</surname><given-names>D</given-names></name><etal/></person-group><article-title>Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients</article-title><source>AIDS</source><year>2010</year><volume>24</volume><fpage>F23</fpage><lpage>F29</lpage><pub-id pub-id-type="doi">10.1097/QAD.0b013e3283391d6d</pub-id><?supplied-pmid 20389235?><pub-id pub-id-type="pmid">20389235</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Castells M, Bello G, Ifr&#x000e1;n S, Pereyra S, Boschi S, Uriarte R, et al. Epidemic history of major genotypes of hepatitis C virus in Uruguay. Infect Genet Evol. 2015;32:231&#x02013;238. doi:10.1016/j.meegid.2015.03.021.</mixed-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taheri</surname><given-names>S</given-names></name><name><surname>Aygen</surname><given-names>B</given-names></name><name><surname>Korkmaz</surname><given-names>K</given-names></name><name><surname>Y&#x00131;ld&#x00131;z</surname><given-names>O</given-names></name><name><surname>Zarars&#x00131;z</surname><given-names>G</given-names></name><name><surname>Canatan</surname><given-names>H</given-names></name></person-group><article-title>Characterization of the interleukin-28B gene rs12979860 C/T polymorphism in Turkish chronic hepatitis C patients and healthy individuals</article-title><source>Balkan Med J</source><year>2015</year><volume>32</volume><fpage>147</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.5152/balkanmedj.2015.15156</pub-id><?supplied-pmid 26167338?><pub-id pub-id-type="pmid">26167338</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montes-Cano</surname><given-names>MA</given-names></name><name><surname>Garc&#x000ed;a-Lozano</surname><given-names>JR</given-names></name><name><surname>Abad-Molina</surname><given-names>C</given-names></name><name><surname>Romero-G&#x000f3;mez</surname><given-names>M</given-names></name><name><surname>Barroso</surname><given-names>N</given-names></name><name><surname>Aguilar-Reina</surname><given-names>J</given-names></name><etal/></person-group><article-title>Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes</article-title><source>Hepatology</source><year>2010</year><volume>52</volume><fpage>33</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1002/hep.23624</pub-id><?supplied-pmid 20578254?><pub-id pub-id-type="pmid">20578254</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knapp</surname><given-names>S</given-names></name><name><surname>Zakaria</surname><given-names>Z</given-names></name><name><surname>Hashem</surname><given-names>M</given-names></name><name><surname>Zaghla</surname><given-names>H</given-names></name><name><surname>Khakoo</surname><given-names>SI</given-names></name><name><surname>Waked</surname><given-names>I</given-names></name><etal/></person-group><article-title>Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians</article-title><source>Hepatol Int</source><year>2015</year><volume>9</volume><fpage>251</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1007/s12072-015-9619-z</pub-id><?supplied-pmid 25788203?><pub-id pub-id-type="pmid">25788203</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharafi</surname><given-names>H</given-names></name><name><surname>Moayed Alavian</surname><given-names>S</given-names></name><name><surname>Behnava</surname><given-names>B</given-names></name><name><surname>Pouryasin</surname><given-names>A</given-names></name><name><surname>Keshvari</surname><given-names>M</given-names></name></person-group><article-title>The impact of IFNL4 rs12979860 polymorphism on spontaneous clearance of hepatitis C; a case-control study</article-title><source>Hepat Mon</source><year>2014</year><volume>14</volume><fpage>e22649</fpage><pub-id pub-id-type="doi">10.5812/hepatmon.22649</pub-id><?supplied-pmid 25419220?><pub-id pub-id-type="pmid">25419220</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mah</surname><given-names>Y-H</given-names></name><name><surname>Liu</surname><given-names>C-H</given-names></name><name><surname>Chen</surname><given-names>C-L</given-names></name><name><surname>Tseng</surname><given-names>T-C</given-names></name><name><surname>Liu</surname><given-names>C-J</given-names></name><name><surname>Chen</surname><given-names>P-J</given-names></name><etal/></person-group><article-title>Prevalence and clinical implications of IL28B genotypes in Taiwanese patients with chronic hepatitis C</article-title><source>J Formos Med Assoc</source><year>2016</year><volume>115</volume><fpage>953</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2016.07.013</pub-id><?supplied-pmid 27751759?><pub-id pub-id-type="pmid">27751759</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Seixas Santos Nastri</surname><given-names>AC</given-names></name><name><surname>de Mello Malta</surname><given-names>F</given-names></name><name><surname>Diniz</surname><given-names>MA</given-names></name><name><surname>Yoshino</surname><given-names>A</given-names></name><name><surname>Abe-Sandes</surname><given-names>K</given-names></name><name><surname>Dos Santos</surname><given-names>SE</given-names></name><etal/></person-group><article-title>Association of IFNL3 and IFNL4 polymorphisms with hepatitis C virus infection in a population from southeastern Brazil</article-title><source>Arch Virol</source><year>2016</year><volume>161</volume><fpage>1477</fpage><lpage>1484</lpage><pub-id pub-id-type="doi">10.1007/s00705-016-2809-8</pub-id><?supplied-pmid 26973228?><pub-id pub-id-type="pmid">26973228</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>NY</given-names></name><name><surname>Lim</surname><given-names>YS</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Oh</surname><given-names>M</given-names></name><name><surname>An</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><etal/></person-group><article-title>No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients</article-title><source>Clin Mol Hepatol</source><year>2014</year><volume>20</volume><fpage>177</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.3350/cmh.2014.20.2.177</pub-id><?supplied-pmid 25032184?><pub-id pub-id-type="pmid">25032184</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moghaddam</surname><given-names>A</given-names></name><name><surname>Melum</surname><given-names>E</given-names></name><name><surname>Reinton</surname><given-names>N</given-names></name><name><surname>Ring-Larsen</surname><given-names>H</given-names></name><name><surname>Verbaan</surname><given-names>H</given-names></name><name><surname>Bj&#x000f8;ro</surname><given-names>K</given-names></name><etal/></person-group><article-title>IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection</article-title><source>Hepatology</source><year>2011</year><volume>53</volume><fpage>746</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1002/hep.24154</pub-id><?supplied-pmid 21374656?><pub-id pub-id-type="pmid">21374656</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharafi</surname><given-names>H</given-names></name><name><surname>Pouryasin</surname><given-names>A</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Behnava</surname><given-names>B</given-names></name><name><surname>Keshvari</surname><given-names>M</given-names></name><name><surname>Salimi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Distribution of IL28B genotypes in Iranian patients with chronic hepatitis C and healthy individuals</article-title><source>Hepat Mon</source><year>2012</year><volume>12</volume><fpage>e8387</fpage><?supplied-pmid 23550102?><pub-id pub-id-type="pmid">23550102</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minakari</surname><given-names>M</given-names></name><name><surname>Golshani</surname><given-names>M</given-names></name><name><surname>Yaran</surname><given-names>M</given-names></name><name><surname>Ataei</surname><given-names>B</given-names></name></person-group><article-title>Prevalence of interleukin-28B single nucleotide polymorphism genotypes in patients with hepatitis C infection in Isfahan, Iran</article-title><source>Adv Biomed Res</source><year>2016</year><volume>5</volume><fpage>90</fpage><pub-id pub-id-type="doi">10.4103/2277-9175.183138</pub-id><?supplied-pmid 27308262?><pub-id pub-id-type="pmid">27308262</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>ZX</given-names></name><name><surname>Zhou</surname><given-names>HJ</given-names></name><name><surname>Xiang</surname><given-names>XG</given-names></name><name><surname>Guo</surname><given-names>SM</given-names></name><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>De</surname><given-names>ZG</given-names></name><etal/></person-group><article-title>IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population</article-title><source>J Dig Dis</source><year>2015</year><volume>16</volume><fpage>90</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1111/1751-2980.12202</pub-id><?supplied-pmid 25312023?><pub-id pub-id-type="pmid">25312023</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mangia</surname><given-names>A</given-names></name><name><surname>De Ledinghen</surname><given-names>V</given-names></name><name><surname>Bailly</surname><given-names>F</given-names></name><name><surname>Brahm</surname><given-names>J</given-names></name><name><surname>Keiss</surname><given-names>J</given-names></name><name><surname>Valantinas</surname><given-names>J</given-names></name><etal/></person-group><article-title>IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational gen-C study</article-title><source>Spring</source><year>2016</year><volume>5</volume><fpage>1990</fpage><pub-id pub-id-type="doi">10.1186/s40064-016-3663-6</pub-id></element-citation></ref></ref-list></back></article>